scispace - formally typeset
Search or ask a question
Institution

Federal University of São Paulo

EducationSão Paulo, Brazil
About: Federal University of São Paulo is a education organization based out in São Paulo, Brazil. It is known for research contribution in the topics: Population & Medicine. The organization has 27971 authors who have published 49365 publications receiving 935536 citations. The organization is also known as: Universidade Federal de São Paulo & Universidade Federal de Sao Paulo.


Papers
More filters
Journal ArticleDOI
Merryn Voysey1, S A Costa Clemens1, Shabir A. Madhi2, Lily Yin Weckx3  +763 moreInstitutions (31)
TL;DR: The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks as discussed by the authors.

862 citations

Journal ArticleDOI
Oliver A. Cornely, Ana Alastruey-Izquierdo1, Dorothee Arenz2, Sharon C.-A. Chen3, Eric Dannaoui4, Bruno Hochhegger5, Bruno Hochhegger6, Martin Hoenigl7, Martin Hoenigl8, Henrik Jeldtoft Jensen9, Katrien Lagrou10, Russell E. Lewis11, Sibylle C. Mellinghoff2, Mervyn Mer12, Zoi D. Pana13, Danila Seidel2, Donald C. Sheppard14, Roger Wahba2, Murat Akova15, Alexandre Alanio16, Abdullah M. S. Al-Hatmi17, Sevtap Arikan-Akdagli15, Hamid Badali18, Ronen Ben-Ami19, Alexandro Bonifaz20, Stéphane Bretagne16, Elio Castagnola21, Methee Chayakulkeeree22, Arnaldo Lopes Colombo23, Dora E. Corzo-Leon24, Lubos Drgona25, Andreas H. Groll26, Jesús Guinea27, Jesús Guinea28, Claus Peter Heussel29, Ashraf S. Ibrahim30, Souha S. Kanj31, Nikolay Klimko, Michaela Lackner32, Frédéric Lamoth33, Fanny Lanternier4, Cornelia Lass-Floerl32, Dong-Gun Lee34, Thomas Lehrnbecher35, Badre E. Lmimouni, Mihai Mares, Georg Maschmeyer, Jacques F. Meis, Joseph Meletiadis36, Joseph Meletiadis37, C. Orla Morrissey38, Marcio Nucci39, Rita O. Oladele, Livio Pagano40, Alessandro C. Pasqualotto41, Atul Patel, Zdenek Racil, Malcolm Richardson, Emmanuel Roilides13, Markus Ruhnke, Seyedmojtaba Seyedmousavi42, Seyedmojtaba Seyedmousavi18, Neeraj Sidharthan43, Nina Singh44, Janos Sinko, Anna Skiada36, Monica A. Slavin45, Monica A. Slavin46, Rajeev Soman47, Brad Spellberg48, William J. Steinbach49, Ban Hock Tan50, Andrew J. Ullmann, Joerg J. Vehreschild35, Maria J G T Vehreschild35, Thomas J. Walsh51, P. Lewis White52, Nathan P. Wiederhold53, Theoklis E. Zaoutis54, Arunaloke Chakrabarti55 
Carlos III Health Institute1, University of Cologne2, University of Sydney3, Paris Descartes University4, Pontifícia Universidade Católica do Rio Grande do Sul5, Universidade Federal de Ciências da Saúde de Porto Alegre6, Medical University of Graz7, University of California, San Diego8, University of Copenhagen9, Katholieke Universiteit Leuven10, University of Bologna11, University of the Witwatersrand12, RMIT University13, McGill University14, Hacettepe University15, University of Paris16, Utrecht University17, Mazandaran University of Medical Sciences18, Tel Aviv University19, Hospital General de México20, Istituto Giannina Gaslini21, Mahidol University22, Federal University of São Paulo23, King's College, Aberdeen24, Comenius University in Bratislava25, Boston Children's Hospital26, Hospital General Universitario Gregorio Marañón27, Complutense University of Madrid28, University Hospital Heidelberg29, University of California, Los Angeles30, American University of Beirut31, Innsbruck Medical University32, University of Lausanne33, Catholic University of Korea34, Goethe University Frankfurt35, National and Kapodistrian University of Athens36, Erasmus University Rotterdam37, Monash University38, Federal University of Rio de Janeiro39, Catholic University of the Sacred Heart40, University of Health Sciences Antigua41, National Institutes of Health42, Amrita Institute of Medical Sciences and Research Centre43, University of Pittsburgh44, Peter MacCallum Cancer Centre45, University of Melbourne46, P. D. Hinduja Hospital and Medical Research Centre47, University of Southern California48, Duke University49, Singapore General Hospital50, NewYork–Presbyterian Hospital51, Cardiff University52, University of Texas Health Science Center at San Antonio53, Children's Hospital of Philadelphia54, Post Graduate Institute of Medical Education and Research55
TL;DR: Management of mucormycosis depends on recognising disease patterns and on early diagnosis, and limited availability of contemporary treatments burdens patients in low and middle income settings.
Abstract: Mucormycosis is a difficult to diagnose rare disease with high morbidity and mortality. Diagnosis is often delayed, and disease tends to progress rapidly. Urgent surgical and medical intervention is lifesaving. Guidance on the complex multidisciplinary management has potential to improve prognosis, but approaches differ between health-care settings. From January, 2018, authors from 33 countries in all United Nations regions analysed the published evidence on mucormycosis management and provided consensus recommendations addressing differences between the regions of the world as part of the "One World One Guideline" initiative of the European Confederation of Medical Mycology (ECMM). Diagnostic management does not differ greatly between world regions. Upon suspicion of mucormycosis appropriate imaging is strongly recommended to document extent of disease and is followed by strongly recommended surgical intervention. First-line treatment with high-dose liposomal amphotericin B is strongly recommended, while intravenous isavuconazole and intravenous or delayed release tablet posaconazole are recommended with moderate strength. Both triazoles are strongly recommended salvage treatments. Amphotericin B deoxycholate is recommended against, because of substantial toxicity, but may be the only option in resource limited settings. Management of mucormycosis depends on recognising disease patterns and on early diagnosis. Limited availability of contemporary treatments burdens patients in low and middle income settings. Areas of uncertainty were identified and future research directions specified.

842 citations

Journal ArticleDOI
TL;DR: This study is the first apnea survey of a large metropolitan area in South America identifying a higher prevalence of OSAS than found in other epidemiological studies and can be explained by the use of the probabilistic sampling process achieving a very low polysomnography refusal rate.

828 citations

Journal ArticleDOI
01 Jul 2018-Allergy
TL;DR: In this paper, an evidence-and consensus-based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group.
Abstract: This evidence- and consensus-based guideline was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. The conference was held on 1 December 2016. It is a joint initiative of the Dermatology Sectionof the European Academy of Allergology and Clinical Immunology (EAACI), the EU-founded network of excellence, the Global Allergy and Asthma European Network (GA(2)LEN), the European Dermatology Forum (EDF) and the World Allergy Organization (WAO) with the participation of 48 delegates of 42 national and international societies. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell-driven disease, presenting with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous urticaria and other chronic forms of urticaria are disabling, impair quality of life and affect performance at work and school. This guideline covers the definition and classification of urticaria, taking into account the recent progress in identifying its causes, eliciting factors and pathomechanisms. In addition, it outlines evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria.

819 citations

Journal ArticleDOI
15 Apr 2015
TL;DR: OCTA is quick and non-invasive, and provides volumetric data with the clinical capability of specifically localizing and delineating pathology along with the ability to show both structural and blood flow information in tandem, its current limitations include a relatively small field of view.
Abstract: Optical coherence tomography angiography (OCTA) is a new, non-invasive imaging technique that generates volumetric angiography images in a matter of seconds. This is a nascent technology with a potential wide applicability for retinal vascular disease. At present, level 1 evidence of the technology’s clinical applications doesn’t exist. In this paper, we introduce the technology, review the available English language publications regarding OCTA, and compare it with the current angiographic gold standards, fluorescein angiography (FA) and indocyanine green angiography (ICGA). Finally we summarize its potential application to retinal vascular diseases. OCTA is quick and non-invasive, and provides volumetric data with the clinical capability of specifically localizing and delineating pathology along with the ability to show both structural and blood flow information in tandem. Its current limitations include a relatively small field of view, inability to show leakage, and proclivity for image artifact due to patient movement/blinking. Published studies hint at OCTA’s potential efficacy in the evaluation of common ophthalmologic diseases such age related macular degeneration (AMD), diabetic retinopathy, artery and vein occlusions, and glaucoma. OCTA can detect changes in choroidal blood vessel flow and can elucidate the presence of choroidal neovascularization (CNV) in a variety of conditions but especially in AMD. It provides a highly detailed view of the retinal vasculature, which allows for accurate delineation of the foveal avascular zone (FAZ) in diabetic eyes and detection of subtle microvascular abnormalities in diabetic and vascular occlusive eyes. Optic disc perfusion in glaucomatous eyes is notable as well on OCTA. Further studies are needed to more definitively determine OCTA’s utility in the clinical setting and to establish if this technology may offer a non-invasive option of visualizing the retinal vasculature in detail.

785 citations


Authors

Showing all 28240 results

NameH-indexPapersCitations
Majid Ezzati133443137171
Christian Guilleminault13389768844
Jean Rivier13376973919
Myron M. Levine12378960865
Werner Seeger114111357464
Katherine L. Tucker10668339404
Michael Bader10373537525
Paulo A. Lotufo89622100527
Fernando Q. Cunha8868231501
Paul R. Sanberg8763529745
Harold A. Chapman8719126617
Ricardo T. Gazzinelli8634028233
Carlito B. Lebrilla8649525415
Roger S. McIntyre8580732040
Sergio Tufik85142435174
Network Information
Related Institutions (5)
University of São Paulo
272.3K papers, 5.1M citations

95% related

Federal University of Rio de Janeiro
89.1K papers, 1.5M citations

92% related

Universidade Federal de Minas Gerais
75.6K papers, 1.2M citations

92% related

State University of Campinas
104.6K papers, 1.8M citations

92% related

Federal University of Paraná
46.6K papers, 546.5K citations

92% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
202372
2022409
20213,982
20203,843
20193,234
20182,898